Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ATC Clear all

Conditions: Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions: XRD-0394, Palliative radiotherapy; Drug · Radiation
Lead sponsor: XRad Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Conditions: Solid Tumor, Unspecified, Adult
Interventions: Determination of ATM alteration status.; Other
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2033
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more

Conditions: Breast Cancer
Interventions: HER2Bi-armed activated T cells, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, laboratory biomarker analysis, neoadjuvant therapy, therapeutic conventional surgery; Biological · Drug · Other + 1 more
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cutaneous Toxicity From ICI Therapy
Interventions: Immune checkpoint inhibitor (ICI); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 2,214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neoplasms
Interventions: Veliparib + VX-970 + Cisplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Bethesda, Maryland • Boston, Massachusetts • Houston, Texas

Conditions: Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
Interventions: Cemiplimab, XL092; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina

Conditions: Alcohol Use Disorder (AUD), Pharmacist-Patient Relations, Alcohol Problem
Interventions: ATC Intervention; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 41,843 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Oakland, California • San Francisco, California

Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions: JZP815; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more

Conditions: Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 6 Months to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: Aldesleukin, Sargramostim, therapeutic autologous lymphocytes; Biological
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT); Biological · Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Non-Small Cell Lung Cancer
Interventions: M1774, Cemiplimab; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Santa Monica, California • Pittsburgh, Pennsylvania • Knoxville, Tennessee + 2 more

Conditions: Ataxia Telangiectasia
Interventions: Antisense oligonucleotide targeting the ATM gene; Drug
Lead sponsor: Timothy Yu; Other
Eligibility: 0 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
Interventions: ART0380, Gemcitabine, Irinotecan; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 46
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more

Conditions: Thyroid Cancer
Interventions: Avutometinib, Defactinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Thyroid
Interventions: Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumours
Interventions: Ceralasertib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan; Drug
Lead sponsor: Actuate Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more

Conditions: Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Thyroid Gland Anaplastic Carcinoma
Interventions: Laboratory Biomarker Analysis, Pazopanib Hydrochloride; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 16
States / cities: Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 13 more

Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions: Secretin, MRI, Tumor marker gene test with CA19-9; Drug · Diagnostic Test · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 9
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Chronic Pain, Postsurgical Pain
Interventions: Oxymorphone hydrochloride (HCl); Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 5
States / cities: Orange, California • New Orleans, Louisiana • Oklahoma City, Oklahoma + 2 more

Conditions: Advanced Solid Tumors
Interventions: Elimusertib (BAY1895344), Pembrolizumab (Keytruda®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more

Search by objective public record fields.

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Alcohol Telemedicine Consultation in Primary Care (ATC)

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Biological Therapy in Treating Women With Stage IV Breast Cancer

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

9-ING-41 in Patients With Advanced Cancers

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

The Cancer of the Pancreas Screening-5 CAPS5)Study

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug